A new era of melanoma treatment

Name: A new era of melanoma treatment
Uploaded: 2009-09-24T01:01:00+00:00
Description: Prof Alexander Eggermont, President of the European CanCer Organisation, talks to Editor Gordon McVie about a new era of melanoma treatment, immunomodulation, combination immunotherapy, ipilimumab's unprecedented success in increasing the 2 year survival rate, the EORTC 18071 trial, BRAF mutations, ECCO's lifetime achievement award and his initiative of 'oncopolicy'.

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 24 Sep 2009

Rating:

Save

Prof Alexander Eggermont - President of the European CanCer Organisation

Prof Alexander Eggermont, President of the European CanCer Organisation, talks to Editor Gordon McVie about a new era of melanoma treatment, immunomodulation, combination immunotherapy, ipilimumab's unprecedented success in increasing the 2 year survival rate, the EORTC 18071 trial, BRAF mutations, ECCO's lifetime achievement award and his initiative of 'oncopolicy'.

Related Videos

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

28 Oct 2024

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 Sep 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$